Glucose Control is Not Improved by Accelerating Gastric Emptying in Patients with Type 1 Diabetes Mellitus and Gastroparesis. A Pilot Study with Cisapride as a Model Drug

 

 Buy Article Permissions and Reprints

Abstract

The present pilot study investigated whether acceleration of gastric emptying in patients with type 1 diabetes and delayed gastric emptying (a possible cause of poorly controlled diabetes) improves long-term glucose control.

Eight outpatients with diabetes (age 28 - 63 years, mean diabetes duration 24.6 ± 6.0 years) and delayed gastric emptying of radio-opaque markers were randomised and treated, for three months each, with a prokinetic drug (cisapride 20 mg twice daily) and placebo. Mean capillary glucose, glucose variability (M-values, MAGE), fructosamine, and HbA1c were assessed. Gastric emptying of a solid standard meal was measured by scintigraphy after each treatment period.

Chronic administration of a prokinetic drug resulted in improved solid gastric emptying (percentage residual) at 120 min (p = 0.025). The percentage residual was 43.6 ± 9.6 % during prokinetic treatment and 59.7 ± 9.9 % during placebo (standard error of paired differences 5.7 %). The mean gastric emptying time (t/2) of solids was 88 min during prokinetic treatment compared to 113 min in the placebo arm (SE of paired differences 14 min; p = 0.09). Mean blood glucose values (9.0 ± 3.8 vs. 8.8 ± 3.7 mmol/l), daily glucose variability (MAGE 6.8 ± 1.3 vs. 6.3 ± 1.6 mmol/l; M-value 15.2 ± 2.5 vs. 13.9 ± 4.5), and HbA1c at 3 months (7.8 ± 1.1 % vs. 7.6 ± 1.0 %) were not statistically different between prokinetic drug and placebo treatment. Similarly, the frequency of hypoglycaemic episodes (≤ 3 mmol/l) was not different in both groups (78 vs. 68).

Our pilot study showed that long-term acceleration of gastric emptying had no effect on overall glycaemic control, the magnitude of glucose excursions, and hypoglycaemic episodes in patients with diabetic gastroparesis. We do not recommend, therefore, acceleration of gastric emptying as treatment strategy for “brittle diabetes” in patients with type 1 diabetes.

References

• 1 Abell T L, Camilleri M, DiMagno E P, Hench V S, Zinsmeister A R, Malagelada J R. Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility.  Dig Dis Sci. 1991;  36 616-620
  CrossrefPubMedGoogle Scholar
• 2 Annese V, Lombardi G, Frusciante V, Germani U, Andriulli A, Bassotti G. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus.  Aliment Pharmacol Ther. 1997;  11 599-603
  CrossrefPubMedGoogle Scholar
• 3 Bedford T A, Rowbotham D J. Cisapride. Drug interactions of clinical significance [published erratum appears in Drug Saf 1997; 17: 196].  Drug Saf. 1996;  15 167-175
  PubMedGoogle Scholar
• 4 Beglinger C. Measurement of gastric emptying and colonic transit time with radio-opaque markers. Janssen Educational Symposium Series, Excerpta Medica. 1994: 1-6
  Google Scholar
• 5 Beglinger C, Meyer-Wyss B, Meier R, Brignoli R. Gastric clearance of radio-opaque markers is modified with different meals. Conference Proceedings, First United European Gastroenterology Week, Athens. 1992
  Google Scholar
• 6 Berne C. Hypoglycaemia and gastric emptying.  Diabet Med. 1996;  13 S28-S30
  PubMedGoogle Scholar
• 7 Borovicka J, Lehmann R, Kunz P, Fraser. F., Kreiss C, Crelier G, Boesiger P, Spinas GA, Fried M, Schwizer W. Evaluation of gastric emptying and motility in diabetic gastroparesis with magnetic resonance imaging: Effects of cisapride.  Am J Gastroenterol. 1999;  94 2866-2873
  CrossrefPubMedGoogle Scholar
• 8 Bran S, Murray W A, Hirsch I B, Palmer J P. Long QT syndrome during high-dose cisapride.  Arch Intern Med. 1995;  155 765-768
  CrossrefPubMedGoogle Scholar
• 9 Camilleri M, Malagelada J R, Abell T L, Brown M L, Hench V, Zinsmeister A R. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction.  Gastroenterology. 1989;  96 704-712
  PubMedGoogle Scholar
• 10 Campbell A, Conway H. Gastric retention and hypoglycemia in diabetes.  Scott Med J. 1960;  5 167-168
  PubMedGoogle Scholar
• 11 Campbell I W, Heading R C, Tothill P, Buist T A, Ewing D J, Clarke B F. Gastric emptying in diabetic autonomic neuropathy.  Gut. 1977;  18 462-467
  PubMedGoogle Scholar
• 12 Chang C S, Lien H C, Yeh H Z, Poon S K, Tung C F, Chen G H. Effect of cisapride on gastric dysrhythmia and emptying of indigestible solids in type-II diabetic patients.  Scand J Gastroenterol. 1998;  33 600-604
  CrossrefPubMedGoogle Scholar
• 13 Collins P J, Horowitz M, Shearman D J, Chatterton B E. Correction for tissue attenuation in radionuclide gastric emptying studies: a comparison of a lateral image method and a geometric mean method.  Br J Radiol. 1984;  57 689-695
  PubMedGoogle Scholar
• 14 Evans A J, Krentz A J. Should cisapride be avoided in patients with diabetic gastroparesis?.  J Diabetes Complications. 1999;  13 314-315
  CrossrefPubMedGoogle Scholar
• 15 Feldman M, Smith H J. Effect of cisapride on gastric emptying of indigestible solids in patients with gastroparesis diabeticorum. A comparison with metoclopramide and placebo.  Gastroenterology. 1987;  92 171-174
  PubMedGoogle Scholar
• 16 Fraser R, Fried M, Beglinger C. Assessment of gastric emptying.  Schweiz Med Wochenschr. 1993;  54 (Suppl) 15-21
  PubMedGoogle Scholar
• 17 Fraser R J, Horowitz M, Maddox A F, Harding P E, Chatterton B E, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus.  Diabetologia. 1990;  33 675-680
  CrossrefPubMedGoogle Scholar
• 18 Gupta K K, Hegde K P, Lal R. Diabetic gastric neuropathy with acute hypoglycaemic attacks.  J Indian Med Assoc. 1971;  57 258-259
  PubMedGoogle Scholar
• 19 Horowitz M, Edelbroek M, Fraser R, Maddox A, Wishart J. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance, and treatment.  Scand J Gastroenterol. 1991;  26 673-684
  PubMedGoogle Scholar
• 20 Horowitz M, Harding P E, Maddox A, Maddern G J, Collins P J, Chatterton B E, Wishart J, Shearman D JC. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus.  J Gastroenterol Hepatol. 1986;  1 97-113
  PubMedGoogle Scholar
• 21 Horowitz M, Harding P E, Maddox A F, Wishart J M, Akkermans L M, Chatterton B E, Shearman D J. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus.  Diabetologia. 1989 b;  32 151-159
  CrossrefPubMedGoogle Scholar
• 22 Horowitz M, Maddox A, Bochner M, Wishart J, Bratasiuk R, Collins P, Shearman D. Relationships between gastric emptying of solid and caloric liquid meals and alcohol absorption.  Am J Physiol. 1989 a;  257 G291-298
  PubMedGoogle Scholar
• 23 Horowitz M, Maddox A, Harding P E, Maddern G J, Chatterton B E, Wishart J, Shearman D J. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus.  Gastroenterology. 1987;  92 1899-1907
  PubMedGoogle Scholar
• 24 Horowitz M, Roberts A P. Long-term efficacy of cisapride in diabetic gastroparesis.  Am J Med. 1990;  88 195-196
  CrossrefPubMedGoogle Scholar
• 25 Ishii K, Tanabe S, Mitsuhashi T, Saigenji K. [Influence on glycemic control of improved diabetic gastroparesis by long-term cisapride therapy].  Nippon Shokakibyo Gakkai Zasshi. 1995;  92 1724-1733
  PubMedGoogle Scholar
• 26 Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K. Altered postprandial insulin requirement in IDDM patients with gastroparesis.  Diabetes Care. 1994;  17 901-903
  PubMedGoogle Scholar
• 27 Janssens J, Peeters T L, Vantrappen G, Tack J, Urbain J L, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies [see comments].  N Engl J Med. 1990;  322 1028-1031
  PubMedGoogle Scholar
• 28 Johansson U B, Wredling R A, Adamson U C, Lins P E. A randomised study evaluating the effects of cisapride on glucose variability and quality of life parameters in insulin-dependent diabetes mellitus patients.  Diabetes Metab. 1999;  25 314-319
  PubMedGoogle Scholar
• 29 Kawagishi T, Nishizawa Y, Okuno Y, Sekiya K, Morii H. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy.  Am J Gastroenterol. 1993;  88 933-938
  PubMedGoogle Scholar
• 30 Kendall B J, Kendall E T, Soykan I, McCallum R W. Cisapride in the long-term treatment of chronic gastroparesis: a 2-year open-label study.  J Int Med Res. 1997;  25 182-189
  PubMedGoogle Scholar
• 31 Keshavarzian A, Iber F L, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus.  Am J Gastroenterol. 1987;  82 29-35
  PubMedGoogle Scholar
• 32 Lehmann R, Borovicka J, Kunz P, Crelier G, Boesiger P, Fried M, Schwizer W, Spinas G A. Evaluation of delayed gastric emptying in diabetic patients with autonomic neuropathy by a new MRI technique and radio-opaque markers.  Diabetes Care. 1996;  19 1075-1082
  PubMedGoogle Scholar
• 33 Mansi C, Savarino V, Vigneri S, Perilli D, Melga P, Sciaba L, De M D, Mela G S. Gastrokinetic effects of levosulpiride in dyspeptic patients with diabetic gastroparesis.  Am J Gastroenterol. 1995;  90 1989-1993
  PubMedGoogle Scholar
• 34 Melga P, Mansi C, Ciuchi E, Giusti R, Sciaba L, Prando R. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis.  Diabetes Care. 1997;  20 55-58
  PubMedGoogle Scholar
• 35 Meyer B M, Werth B A, Beglinger C, Hildebrand P, Jansen J B, Zach D, Rovati L C, Stalder G A. Role of cholecystokinin in regulation of gastrointestinal motor functions.  Lancet. 1989;  2 12-15
  PubMedGoogle Scholar
• 36 Oster-Jorgensen E, Pedersen S A, Larsen M L. The influence of induced hyperglycaemia on gastric emptying in healthy humans.  Scand J Clin Lab Invest. 1990;  50 831-836
  PubMedGoogle Scholar
• 37 Rothstein R D, Alavi A, Reynolds J C. Electrogastrography in patients with gastroparesis and effect of long-term cisapride.  Dig Dis Sci. 1993;  38 1518-1524
  CrossrefPubMedGoogle Scholar
• 38 Schapira M, Henrion J, Heller F R. The current status of gastric prokinetic drugs.  Acta Gastroenterol Belg. 1990;  53 446-457
  PubMedGoogle Scholar
• 39 Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus.  Gastroenterology. 1997;  113 60-66
  CrossrefPubMedGoogle Scholar
• 40 Stacher G, Schernthaner G, Francesconi M, Kopp H P, Bergmann H, Stacher J G, Weber U. Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial.  J Clin Endocrinol Metab. 1999;  84 2357-2362
  CrossrefPubMedGoogle Scholar
• 41 Ueno N, Inui A, Asakawa A, Takao F, Tani S, Komatsu Y, Itoh Z, Kasuga M. Erythromycin improves glycaemic control in patients with Type II diabetes mellitus.  Diabetologia. 2000;  43 411-415
  CrossrefPubMedGoogle Scholar
• 42 Werth B, Meyer-Wyss B, Spinas G A, Drewe J, Beglinger C. Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with and without cardiovascular signs of autonomic neuropathy.  Gut. 1992;  33 1199-1203
  PubMedGoogle Scholar
• 43 Wojcicki J M. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull “M”-value.  Horm Metab Res. 1995;  27 1-5
  PubMedGoogle Scholar

M.D. Roger Lehmann

Division of Endocrinology and Diabetes
University Hospital

Zurich

Raemistrasse 100

8091 Zürich

Switzerland

Phone: + 4112551111

Fax: + 41 12 55 44 47

Email: Roger.Lehmann@dim.usz.ch